


MUVON

—
Regain control through
personalized muscle
regeneration

MUVON



Contact

Deana Mohr-Haralampieva
Project Leader
+41 (0)75 432 30 17
deana.mohr@wysszurich.ch

Partners

Horizon 2020
Scinus Cell Expansion TM
Collagen Solutions
University of Tübingen
Paracelsus Medical University

Mentor

Prof. Dr. Dr. med. Daniel Eberli

Startup website

www.muvon-therapeutics.com

Regain control through personalized muscle regeneration

Stress urinary incontinence (SUI) is a highly prevalent and under-diagnosed disorder, which affects over 200 million people worldwide. It has a severe impact on physical and psychological health, and imposes a high financial burden on affected individuals, healthcare systems and society.

Women are affected twice as often as men, with an estimated 40% of women above the age of 40 suffering from SUI. All existing treatment options have drawbacks that range from low and short-term efficacy (for conservative treatments) to potentially serious adverse events associated either with invasiveness or the introduction of foreign material (for more potent surgical approaches).

MUVON is developing a low-risk, minimally invasive treatment that uses the patient's own muscle precursor cells (MPC) to regenerate the damaged sphincter muscle, thus potentially providing a cure for SUI.

Before the founding of MUVON, the team worked in the Associate project MUS.I.C. to establish and validate its GMP-compliant production process at the Wyss Zurich. This was followed by a translation into a clinical setting beginning of 2020 and the conduction of a Phase I clinical trial. With the support of Wyss Zurich the MUVON team will proceed with the clinical and commercial development of their therapy, evaluating the efficacy of the approach during a phase II clinical trial and undertaking all the required activities for a regulatory approval.



MUVON
is a Wyss Zurich project
www.wysszurich.ch